(Q36407383)

14 August 2017

1 reference

title

Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality (English)

1 reference

14 August 2017

1

Andreas Pfützner

1 reference

14 August 2017

Thomas Forst

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

463-476

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pathogenesis of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Insulin resistance and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

21 January 2018

Rosiglitazone/Metformin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Thiazolidinediones: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

PPARgamma, the ultimate thrifty gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Thiazolidinedione-induced edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Fatal liver failure associated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Second-generation thiazolidinediones and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.463

21 January 2018

Identifiers

DOI

10.1517/14656566.7.4.463

1 reference

14 August 2017

1 reference